派姆单抗联合化疗治疗肺腺癌期间COVID-19感染

IF 0.3 Q4 ONCOLOGY
M. Wójcik-Superczyńska
{"title":"派姆单抗联合化疗治疗肺腺癌期间COVID-19感染","authors":"M. Wójcik-Superczyńska","doi":"10.5603/ocp.2022.0023","DOIUrl":null,"url":null,"abstract":"The use of pembrolizumab with chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) is an opportunity for patients to suppress their disease and increase their chances of life extension. COVID-19 (Coronavirus Disease 2019) vaccination is an opportunity for cancer patients to reduce their risk of disease and have a benign disease course. In this report, we present a benign course of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection in 68-year-old patient with metastatic lung adenocarcinoma undergoing chemoimmunotherapy who had previously received full COVID-19 vaccination. The control CT scans performed after 3 months of treatment showed partial regression of the tumor mass. On control tomography after 6 months, an intensification of fibro-consolidative changes and ground glass opacities were described. The lesions were characteristic of a history of SARS-CoV-2 infection. The neoplastic lesions described on tomography showed stabilization. After 9 months, long-term stabilization of the disease was achieved. Patients undergoing immunotherapy or chemoimmunotherapy may be at risk of developing severe COVID-19. Therefore, vaccination against SARS-CoV-2 should be strongly recommended in lung cancer patients undergoing immunotherapy. Copyright © 2022 Via Medica.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"48 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 infection during treatment with pembrolizumab in combination with chemotherapy for the treatment of lung adenocarcinoma\",\"authors\":\"M. Wójcik-Superczyńska\",\"doi\":\"10.5603/ocp.2022.0023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The use of pembrolizumab with chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) is an opportunity for patients to suppress their disease and increase their chances of life extension. COVID-19 (Coronavirus Disease 2019) vaccination is an opportunity for cancer patients to reduce their risk of disease and have a benign disease course. In this report, we present a benign course of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection in 68-year-old patient with metastatic lung adenocarcinoma undergoing chemoimmunotherapy who had previously received full COVID-19 vaccination. The control CT scans performed after 3 months of treatment showed partial regression of the tumor mass. On control tomography after 6 months, an intensification of fibro-consolidative changes and ground glass opacities were described. The lesions were characteristic of a history of SARS-CoV-2 infection. The neoplastic lesions described on tomography showed stabilization. After 9 months, long-term stabilization of the disease was achieved. Patients undergoing immunotherapy or chemoimmunotherapy may be at risk of developing severe COVID-19. Therefore, vaccination against SARS-CoV-2 should be strongly recommended in lung cancer patients undergoing immunotherapy. Copyright © 2022 Via Medica.\",\"PeriodicalId\":42942,\"journal\":{\"name\":\"Oncology in Clinical Practice\",\"volume\":\"48 1\",\"pages\":\"\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology in Clinical Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/ocp.2022.0023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology in Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ocp.2022.0023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在晚期非小细胞肺癌(NSCLC)患者的一线治疗中,使用派姆单抗联合化疗是患者抑制疾病和增加延长生命机会的机会。COVID-19(2019冠状病毒病)疫苗接种是癌症患者降低疾病风险并实现良性病程的机会。在本报告中,我们报告了68岁的转移性肺腺癌患者在接受化学免疫治疗后感染SARS-CoV-2(严重急性呼吸综合征冠状病毒2)的良性过程,该患者之前接受了COVID-19疫苗接种。治疗3个月后进行的对照CT扫描显示肿瘤肿块部分消退。6个月后的对照断层扫描显示纤维实变强化和磨玻璃浊影。这些病变具有SARS-CoV-2感染史的特征。在断层扫描上描述的肿瘤病变显示稳定。9个月后,实现了疾病的长期稳定。接受免疫治疗或化学免疫治疗的患者可能有发展为严重COVID-19的风险。因此,强烈建议接受免疫治疗的肺癌患者接种SARS-CoV-2疫苗。版权所有©2022 Via Medica
本文章由计算机程序翻译,如有差异,请以英文原文为准。
COVID-19 infection during treatment with pembrolizumab in combination with chemotherapy for the treatment of lung adenocarcinoma
The use of pembrolizumab with chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) is an opportunity for patients to suppress their disease and increase their chances of life extension. COVID-19 (Coronavirus Disease 2019) vaccination is an opportunity for cancer patients to reduce their risk of disease and have a benign disease course. In this report, we present a benign course of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection in 68-year-old patient with metastatic lung adenocarcinoma undergoing chemoimmunotherapy who had previously received full COVID-19 vaccination. The control CT scans performed after 3 months of treatment showed partial regression of the tumor mass. On control tomography after 6 months, an intensification of fibro-consolidative changes and ground glass opacities were described. The lesions were characteristic of a history of SARS-CoV-2 infection. The neoplastic lesions described on tomography showed stabilization. After 9 months, long-term stabilization of the disease was achieved. Patients undergoing immunotherapy or chemoimmunotherapy may be at risk of developing severe COVID-19. Therefore, vaccination against SARS-CoV-2 should be strongly recommended in lung cancer patients undergoing immunotherapy. Copyright © 2022 Via Medica.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.90
自引率
20.00%
发文量
46
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信